[go: up one dir, main page]

ES2116594T3 - Ansamicinas biciclicas y su uso como agentes antitumorales. - Google Patents

Ansamicinas biciclicas y su uso como agentes antitumorales.

Info

Publication number
ES2116594T3
ES2116594T3 ES94913896T ES94913896T ES2116594T3 ES 2116594 T3 ES2116594 T3 ES 2116594T3 ES 94913896 T ES94913896 T ES 94913896T ES 94913896 T ES94913896 T ES 94913896T ES 2116594 T3 ES2116594 T3 ES 2116594T3
Authority
ES
Spain
Prior art keywords
ansamicins
bicyclic
antitumoral agents
sup
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94913896T
Other languages
English (en)
Inventor
Rodney C Schnur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of ES2116594T3 publication Critical patent/ES2116594T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

ESTA INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA (I) EN DONDE R{SUP, 1}, R{SUP, 2}, R{SUP, 3} Y X SON SEGUN SE DEFINE EN LA DESCRIPCION. TALES COMPUESTOS SON UTILES COMO INHIBIDORES DE LOS ONCOGENES Y COMO AGENTES ANTITUMORALES.
ES94913896T 1993-04-07 1994-03-14 Ansamicinas biciclicas y su uso como agentes antitumorales. Expired - Lifetime ES2116594T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/044,521 US5387584A (en) 1993-04-07 1993-04-07 Bicyclic ansamycins

Publications (1)

Publication Number Publication Date
ES2116594T3 true ES2116594T3 (es) 1998-07-16

Family

ID=21932854

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94913896T Expired - Lifetime ES2116594T3 (es) 1993-04-07 1994-03-14 Ansamicinas biciclicas y su uso como agentes antitumorales.

Country Status (10)

Country Link
US (1) US5387584A (es)
EP (1) EP0693073B1 (es)
JP (1) JP2722280B2 (es)
AT (1) ATE166877T1 (es)
CA (1) CA2160137C (es)
DE (1) DE69410790T2 (es)
DK (1) DK0693073T3 (es)
ES (1) ES2116594T3 (es)
FI (1) FI106028B (es)
WO (1) WO1994022867A1 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852496B1 (en) 1997-08-12 2005-02-08 Oregon Health And Science University Methods of screening for agents that promote nerve cell growth
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
EP1098666B1 (en) 1998-07-17 2013-01-16 The United States of America, represented by the Secretary, Department of Health and Human Services Water-soluble drugs and methods for their production
US6747055B1 (en) 1998-07-17 2004-06-08 The United States Of America As Represented By The Department Of Health And Human Services Water-soluble drugs and methods for their production
AU2167000A (en) * 1998-12-07 2000-06-26 Ecosmart Technologies, Inc. Cancer treatment composition and method using natural plant essential oils
US6946456B2 (en) * 2000-07-28 2005-09-20 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
CA2426952C (en) * 2000-11-02 2012-06-26 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
US7211562B2 (en) 2000-11-02 2007-05-01 Sloan-Kettering Institute For Cancer Research Methods for enhancing the efficacy of cytotoxic agents through the use of HSP90 inhibitors
EP1423080A4 (en) * 2001-03-01 2009-06-03 Conforma Therapeutics Corp PROCESS FOR TREATING PROLIFERATIVE GENETIC DISORDERS WITH HSP90 INHIBITORS
JP2004529188A (ja) * 2001-05-23 2004-09-24 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 上昇に関連した癌の治療法
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
EP1923061A1 (en) 2001-09-24 2008-05-21 Conforma Therapeutic Corporation Process for preparing 17-Allyl amino geldanamycin (17-AAG) and other ansamycins
ATE387198T1 (de) * 2001-09-24 2008-03-15 Conforma Therapeutic Corp Verfahren zur herstellung von 17-allyl-amino- geldanamycin (17-aag) und anderer ansamycine
US7261875B2 (en) 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
CA2474508A1 (en) * 2002-02-08 2003-08-14 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
CA2481683A1 (en) * 2002-04-10 2003-10-23 Conforma Therapeutics Corporation Ansamycin formulations and methods for producing and using same
US20060148776A1 (en) * 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20050054625A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US20050054589A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US7691838B2 (en) * 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
WO2005009345A2 (en) * 2003-06-13 2005-02-03 Kosan Biosciences, Inc. 2-desmethyl ansamycin compounds
CN100404029C (zh) * 2003-09-25 2008-07-23 中国医学科学院医药生物技术研究所 格尔德霉素（c-3559）在制备疱疹病毒生殖道感染药物中的应用
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6855705B1 (en) 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6875863B1 (en) 2003-11-12 2005-04-05 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
CA2545457A1 (en) 2003-11-12 2005-06-23 Kosan Biosciences, Inc. 11-o-methylgeldanamycin compounds
US20060019941A1 (en) * 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
CA2547343C (en) 2003-12-23 2013-05-14 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins for the treatment of cancer
WO2005072766A2 (en) * 2004-01-27 2005-08-11 Boys Town National Research Hospital Peptides that bind to hsp90 proteins
US20080171687A1 (en) * 2004-09-16 2008-07-17 Abraxis Bioscience, Inc. Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs
US20060067953A1 (en) * 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
JP2008534609A (ja) * 2005-03-30 2008-08-28 コンフォーマ・セラピューティクス・コーポレイション Ｈｓｐ９０阻害剤としてのアルキニルピロロピリミジンおよび関連類似体
BRPI0608661A2 (pt) * 2005-04-07 2010-01-19 Conforma Therapeutics Corp formulaÇço farmacÊutica, uso de formulaÇço farmacÊutica, e, mÉtodo de preparaÇço de uma formulaÇço farmacÊutica
US7691392B2 (en) * 2005-04-29 2010-04-06 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either
WO2006119032A1 (en) * 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either in combination with a proteasome inhibitor
US20080032719A1 (en) * 2005-10-01 2008-02-07 Outland Research, Llc Centralized establishment-based tracking and messaging service
EP1906950A4 (en) * 2005-06-21 2008-09-24 Infinity Discovery Inc ANSAMYCIN FORMULATIONS AND METHODS OF USE
US20070105874A1 (en) * 2005-09-23 2007-05-10 Conforma Therapeutics Corporation Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors
JP2009518302A (ja) * 2005-12-01 2009-05-07 コンフォーマ・セラピューティクス・コーポレイション アンサマイシン含有組成物
EP2054506A1 (en) 2006-08-15 2009-05-06 Agency for Science, Technology and Research Mesenchymal stem cell conditioned medium
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
US7855192B2 (en) * 2007-01-26 2010-12-21 Kosan Biosciences, Inc. Macrolactams by engineered biosynthesis
AU2008240179A1 (en) * 2007-04-12 2008-10-23 Infinity Discovery, Inc. Hydroquinone ansamycin formulations
AU2008240153B2 (en) * 2007-04-12 2013-01-31 Joyant Pharmaceuticals, Inc. SMAC mimetic dimers and trimers useful as anti-cancer agents
US8466140B2 (en) * 2007-09-10 2013-06-18 University Of Massachusetts Mitochondria-targeted anti-tumor agents
US7960420B2 (en) * 2007-12-21 2011-06-14 Joyant Pharmaceuticals, Inc Diazonamide analogs with improved solubility
HRP20150510T1 (hr) 2008-02-22 2015-06-05 Agency For Science, Technology, And Research (A*Star) Äśestice mezenhimskih matiäśnih stanica
US8716018B2 (en) 2008-03-17 2014-05-06 Agency For Science, Technology And Research Microcarriers for stem cell culture
WO2009134938A1 (en) * 2008-04-29 2009-11-05 Joyant Pharmaceuticals, Inc. Indoline anti-cancer agents
WO2009143485A1 (en) * 2008-05-22 2009-11-26 Joyant Pharmaceuticals, Inc. Diazonamide analogs
CA2739928A1 (en) 2008-10-15 2010-04-22 Infinity Pharmaceuticals, Inc. Ansamycin hydroquinone compositions
US20120283120A1 (en) 2009-09-29 2012-11-08 Takeda Pharmaceutical Company Limited Screening method
WO2011059763A2 (en) 2009-10-28 2011-05-19 Joyant Pharmaceuticals, Inc. Dimeric smac mimetics
SG2014010698A (en) 2009-11-02 2014-05-29 Agency Science Tech & Res Methods of monitoring cellular states
SG183579A1 (en) 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
HRP20171930T1 (hr) 2011-04-22 2018-02-09 Joyant Pharmaceuticals, Inc. Analozi diazonamida
EP3795694A3 (en) 2012-10-02 2021-06-23 The General Hospital Corporation d/b/a Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
AU2014293011A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Compositions to improve the therapeutic benefit of bisantrene
WO2015140005A1 (en) 2014-03-19 2015-09-24 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Method of generation of pluripotent cells
CN110087658A (zh) 2016-10-12 2019-08-02 新加坡科技研究局 一种用于冻干外泌体的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987035A (en) * 1974-04-05 1976-10-19 University Of Illinois Foundation Biologically active compounds
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug

Also Published As

Publication number Publication date
JPH08503960A (ja) 1996-04-30
CA2160137A1 (en) 1994-10-13
FI941580A0 (fi) 1994-04-06
ATE166877T1 (de) 1998-06-15
CA2160137C (en) 1999-02-09
EP0693073B1 (en) 1998-06-03
US5387584A (en) 1995-02-07
DK0693073T3 (da) 1998-10-12
EP0693073A1 (en) 1996-01-24
WO1994022867A1 (en) 1994-10-13
JP2722280B2 (ja) 1998-03-04
FI941580L (fi) 1994-10-08
DE69410790T2 (de) 1998-10-01
DE69410790D1 (de) 1998-07-09
FI106028B (fi) 2000-11-15

Similar Documents

Publication Publication Date Title
ES2116594T3 (es) Ansamicinas biciclicas y su uso como agentes antitumorales.
ES2106965T3 (es) Nuevas 4-aza-5alfa-androstan-3-onas 7beta-sustituidas como inhibidores de 5alfa-reductasa.
ES2080739T3 (es) Nitro-compuestos insecticidamente activos.
MX9102407A (es) 4 arilpiperazinas y 4-arilpiperidinas novedosas.
ES2184797T3 (es) Uso de antagonistas de serotonina (5ht3) para el tratamiento de la fibromialgia.
ES2161220T3 (es) 9-((glicil sustituido)amido)-6-desmetil-6-desoxitetraciclinas como agentes antibioticos.
ES2183331T3 (es) Inhibidores de sulfamida-metaloproteasa.
ES2134226T3 (es) Derivados de s-triazina como fotoestabilizadores.
ES2138622T3 (es) Derivados de mercaptoacetilamido piridazo(1,2-a)(1,2)diazepina utilizados como inhibidores de encefalinasa y eca.
ES2119831T3 (es) 7-(sustituido)-9-((glicil sustituido)amido)-6-desmetil-6-desoxitetraciclinas.
MY107158A (en) 3-arylcarbonyl; -1h-indoles useful as therapeutic agents.
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
MX9700557A (es) Dihidrobenzofuranos.
ES2162617T3 (es) Nuevas 7-(sustituido)-8-(sustituido)-9-((glicilo sustituido)amido)-6-desmetil-6-desoxitetraciclinas.
FI950179L (fi) Kuplautuvia koostumuksia
ES2173876T3 (es) Nuevas 7-(sustituido)-8-(sustituido)-9-(amino sustituido)-6-desmetil-desoxitetraciclinas como agentes antibioticos.
MY111201A (en) New imidazopyridines
MX9205678A (es) Heteroarilaminas como nuevos inhibidores de la acetilcolinesterasa.
MX9302931A (es) Nuevas 4-aza-5&-colestan-onas 7b-substituidas como inhibidores de 5&-reductasa.
ES2062374T3 (es) Heteroarilpiperazinas, agentes antipsicoticos.
ES2134777T3 (es) Nuevos compuestos de sulfonilo.
ES2188984T3 (es) Procedimiento de enriquecimiento en r de epimeros de derivados de 16,17-acetales de derivados de 21-aciloxi-pregnano-1,4-dieno-11-beta, 16alfa-triol-3,20-dionas.
MX9302116A (es) Compuestos azabiciclo.
JO1704B1 (en) New potent compounds

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 693073

Country of ref document: ES